Pyrazolopyridine derivatives and uses thereof

US12172984B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Simone BONAZZI · Cambridge, US
• Artiom CERNIJENKO · Cambridge, US
• Jennifer Stroka Cobb · Stow, US
• Natalie Dales · Arlington, US
• Janetta Dewhurst · Framingham, US
• Matthew James HESSE · Oakland, US
• Rama Jain · Danville, US
• John Ryan Kerrigan · Wakefield, US
• Hasnain Ahmed Malik · Boston, US
• James R. MANNING · Pleasant Hill, US
• Gary O'Brien · Maynard, US
• Andrew W. Patterson · Somerville, US
• Noel Marie-France Thomsen · Cambridge, US
• Pamela YF TING · Somerville, US

Key dates

• Filing date: Sep 1, 2023
• Grant date: Dec 24, 2024
• Expiry date: Sep 1, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.